Boston Scientific (BSX) Q3 2026 Earnings Call Transcript
Boston Scientific reported third-quarter consolidated revenue of $5.14 billion, up 1.5%. [[fact:fact-qclk6ci24]] Third-quarter adjusted EPS was $0.73, down 3% year over year. [[fact:fact-jqwfcv3p2]] Management estimated that the cybersecurity incident had a net negative impact of approximately 300 basis points on third-quarter organic revenue growth. [[fact:fact-y3jeol7rl]] Management expects fourth-quarter operational and organic revenue to decline 1% to 3%. [[fact:fact-sxjgx80xf]] Management expects full-year 2026 operational and organic revenue growth of approximately 3.75%. [[fact:fact-hy5s2qs34]] The CEO said the company expects challenges to growing sales and adjusted EPS in 2027 excluding the pending Penumbra acquisition. [[fact:fact-bhzqty9r5]] The company also entered an agreement with Blackstone Life Sciences to co-fund development of the Vitalist circulatory support system. [[fact:fact-dfkjlm07f]]